Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy

SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that following late-cycle review interactions with the U.S. Food and Drug Administration (FDA), the Company expects the previously assigned...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news